FGFR1 and lung carcinoma: These FGFR1-amplified lung cancer cells showed primary resistance to the FGFR inhibitors AZD4547 or erdafitinib and were characterized by sustained MAPK pathway activation from constitutive MET and RAS activation, as well as deletion of DUSP6, a negative regulator of MAPK signaling [87].